In addition to Dr. Bhalla’s appointment, Lexeo announced the following updates: Jose Manuel Otero, PhD has been appointed COO, transitioning from his role as Chief Technical Officer, effective immediately. Hayes Dansky, MD has joined Lexeo as Vice President, Late-Stage Cardiology Development. He most recently served as Vice President of Innovation at Novo Nordisk’s Bio Innovation Hub, supporting cardiometabolic disease initiatives, and previously served as Head of Clinical Development at Roivant and Sumitovant. Greg Aubert, MD, PhD has been named Vice President, Early-Stage Cardiology Development and Translational Science. He previously served as the Director of the Clinical and Translational Research Division at the Loyola University Cardiovascular Research Institute, where he founded the institution’s Cardiovascular Genetics Clinic, and later led late-stage clinical trials at CSL Vifor.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- Lexeo Therapeutics price target lowered to $10 from $13 at H.C. Wainwright
- Lexeo Therapeutics Reports Positive Interim HEROIC-PKP2 Trial Results
- Lexeo Therapeutics Inc trading resumes
- Lexeo Therapeutics Inc trading halted, volatility trading pause
- Lexeo announces preliminary data from HEROIC-PKP2 Phase I/II trial
